Diagnosis, Innovation

Do Alzheimer’s Blood Tests Replace the Need for Cognitive Screening?

Excitement about the effectiveness and availability of blood biomarker testing for Alzheimer’s disease (AD) has created confusion around whether there’s still a need for other important tools, like cognitive screening. The answer is simple. Cognitive screening is integral to monitoring brain function and identifying impairment in older adults. (But even cognitive screening makers like Neurotrack […]

Read more
featured, Innovation

Are You Complying with CMS Requirements? 6 Things to Consider

The Centers for Medicare and Medicaid Services (CMS) have taken significant steps to improve cognitive care for Medicare beneficiaries. In fact, detecting cognitive impairment is a required element of annual wellness visits (AWV). However, many healthcare providers struggle to implement effective and efficient cognitive screening strategies, resulting in missed opportunities for early detection and care.  […]

Read more
Innovation

Neurotrack Expands C-suite with New Chief Growth Officer to Accelerate Partnerships in Health System and Provider Markets

New hire to drive business expansion amid exciting advances in Alzheimer’s treatment and care (PRESS RELEASE) Neurotrack, the leader in science-backed cognitive health solutions, announced Shawn Lemerise as its first Chief Growth Officer to support the company’s expanding business. With more than 20 years of healthcare experience, Shawn brings his expertise in the health system and provider […]

Read more
featured, Innovation

Neurotrack Develops 3-Minute Digital Test to Screen for Cognitive Impairment

The Digital Exam Enables Providers, For The First Time Ever, To Quickly Screen Brain Health During A Typical 40-Minute Wellness Appointment, More Efficiently And Accurately Signaling Early Signs Of Cognitive Decline (PRESS RELEASE) Neurotrack, the leader in science-backed cognitive health solutions, announced today the launch of the first ever three-minute digital cognitive assessment that enables […]

Read more
Innovation, Memory, Prevention

When One Door Closes

What the Failure of Biogen’s Aducanumab Tells Us About Alzheimer’s — Risk Reduction is Still Our Best Weapon Today I serve as Neurotrack’s Head Writer. But three years ago, in a different professional incarnation, I had the privilege of sitting in a packed conference room with a bright, articulate representative from the pharmaceutical company Biogen […]

Read more